Moderate drinking may cut diabetes risk, study says
NEW YORK A study published last week in the American Journal of Clinical Nutrition found that a moderate consumption of alcohol — one to two drinks per day — may lower one’s risk of diabetes.
Researchers surveyed more than 35,000 Dutch adults over a decade, and found that those who averaged a drink or two per day were 45% less likely to develop Type 2 diabetes than those who abstain from consuming alcoholic beverages. Although the results do not necessarily prove drinking lowers one’s risk of developing diabetes, but the connection should not be written off.
“Our results indicate that this is very unlikely, because moderate drinkers with the most healthy lifestyle behaviors…had a lower chance of developing diabetes compared with subjects with these healthy lifestyle behaviors who did not drink,” lead researcher r. Michel M. Joosten, of Wageningen University in the Netherlands, told Reuters, adding that moderate drinking “can be part of a healthy lifestyle to lower your risk of Type 2 diabetes, even if you already comply with multiple other low-risk lifestyle (behaviors).”
NACDS Foundation elects new board members
ALEXANDRIA, Va. The charitable arm of the National Association of Chain Drug Stores has appointed seven new members to its board of directors.
New members of the NACDS Foundation each will serve one-year term, the organization said. Newly elected NACDS Foundation board members include:
- Joseph W. Cavaliere, SVP customer development of Unilever;
- Debbie B. Garza, divisional VP government and community relations at Walgreens;
- William Graham, VP sales at Beiersdorf;
- David Klaum, general manager of Fougera and Nycomed US SVP;
- Louis J. Martire, VP trade development of Energizer Holdings;
- David A. Moules, VP channel development, patient assistance and reimbursement programs of GlaxoSmithKline; and,
- Robert Potter, SVP sales and marketing of Mylan Pharmaceuticals.
“The NACDS Foundation is dedicated to improving and advancing public health and wellness,” said NACDS Foundation president Edith A. Rosato. “Our board, which is truly representative of the pharmacy community –– from retailers and pharmaceutical companies to consumer product businesses –– shares in our commitment to education, research and charity. I applaud the pharmacy community’s support of the Foundation, welcome our new Board members, and look forward to working with them to implement the foundation’s vision and mission.”
Judge upholds patent for Protonix DR
JERUSALEM The U.S. District Court for the District of New Jersey has ruled that a patent covering a drug for gastroesophageal reflux disease is valid, Teva said.
A jury found that U.S. Patent No. 4,758,579, covering the drug Protonix DR (pantoprazole sodium) was valid, though a decision by the District Court judge independent of the jury’s verdict could still invalidate it.
Wyeth marketed the drug before its acquisition by Pfizer last year. Teva began shipping its generic version in December 2007.